Detalhe da pesquisa
1.
MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.
FASEB J
; 32(5): 2878-2890, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29401593
2.
Structural model of a2-subunit N-terminus and its binding interface for Arf-GEF CTH2: Implication for regulation of V-ATPase, CTH2 function and rational drug design.
Curr Top Membr
; 83: 77-106, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31196611
3.
An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity.
J Clin Invest
; 133(12)2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317966
4.
Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity.
Front Oncol
; 11: 644608, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33747968
5.
Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies.
Cancer Chemother Pharmacol
; 85(2): 461-468, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31811421
6.
Functional significance of VEGFR-2 on ovarian cancer cells.
Int J Cancer
; 124(5): 1045-53, 2009 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19058181
7.
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.
Methods Mol Biol
; 525: 545-57, xv, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19252838
8.
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
Anticancer Res
; 29(6): 1999-2007, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19528458
9.
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.
Bioorg Med Chem
; 17(2): 731-40, 2009 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19101155
10.
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Cancer Res
; 67(2): 593-9, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17234768
11.
Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Clin Cancer Res
; 13(5): 1540-51, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17332300
12.
Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Clin Cancer Res
; 13(24): 7432-40, 2007 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18094427
13.
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Clin Cancer Res
; 13(18 Pt 2): 5549s-5555s, 2007 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17875788
14.
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Clin Cancer Res
; 12(7 Pt 1): 2197-207, 2006 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16609035
15.
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Clin Cancer Res
; 12(21): 6573-84, 2006 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17085673
16.
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
Mol Cancer Ther
; 4(3): 369-79, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15767546
17.
ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.
Sci Signal
; 9(437): ra73, 2016 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27436361
18.
Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury.
J Neuroimmunol
; 125(1-2): 59-65, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11960641
19.
Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.
Cancer Genomics Proteomics
; 9(2): 77-92, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22399498
20.
Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
Anticancer Res
; 31(6): 2149-60, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21737635